Chronic Obstructive Pulmonary Disease : Tunisian Society of Respiratory Diseases and Allergology Guidelines

##plugins.themes.academic_pro.article.sidebar##

Published Mar 15, 2018
Download
pdf
Vol. 95 No. 8 (2017): Issue Aug 2017

##plugins.themes.academic_pro.article.main##

Samy Kammoun
Abdelaziz Hayouni
Hedia Ghrairi
Hajer Racil
Naceur Rouetbi
Abdelhamid Garrouche
Imen Gargouri
Ridha Ben Younes
Anis Maatallah
Souhaiel Slama
Mohamed Smaoui
Faiçal Bali
Fatma Tritar
Mohamed Ridha Charfi

##plugins.themes.academic_pro.article.details##

References

  1. Albert RK, Connett J, Bailey WC, et al; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689-698.
  2. Bridevaux PO, Probst-Hensch NM, Schindler C, et al. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. The European respiratory journal. Dec 2010;36(6):1259-1269.
  3. Calverley P, Pauwels R, Vestbo J, et al; Trial of inhaled steroids and long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449-456.
  4. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
  5. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD002309.
  6. DE Torres JP, Casanova C, Marin JM, et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax. Sep 2014;69(9):799-804.
  7. Denis E O'Donnell, Paul Hernandez, Alan Kaplan et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update ; Can Respir J Vol 15 Suppl A January/February 2008.
  8. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695-703.
  9. Global initiative for chronic obstructive lund disease. Global initative for chronic obstructive lung disease: a global strategy for the diagnosiss, management and prevention of chronic obstructive pulmonary disease 2017
  10. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2013;11:CD009764.
  11. Jadwiga A. Wedzicha et Donald Banerji,Kenneth R. Chapman, al, FLAME investigators. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016; 374:2222-34.
  12. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. American journal of respiratory and critical care medicine. Nov 15
  13. Magnussen H, Disse B, Rodriguez-Roisin R et al ; Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 Oct 2;371(14):1285-94.
  14. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. The Cochrane database of systematic reviews. 2015;2:CD003793.
  15. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014; 50: Suppl. 1, 1-16
  16. Mohangoo AD, van der Linden MW, Schellevis FG, Raat H. Prevalence estimates of asthma or COPD from a health interview survey and from general practitioner registration: what's the difference? European journal of public health. Feb 2006;16(1):101-105.
  17. Mohamed AwadTageldin, SalimNafti, ,Javaid Ahmed Khan et al ; Distribution of COPD-related symptoms in the Middle East and North Africa: Results of the BREATHE study ; Respiratory Medicine (2012) 106(S2), S25-S32.
  18. National Institute for Health and Care Excellence. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (Partial Update). Date last updated: 2010.
  19. Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Annals of internal medicine. Nov 6 2007;147(9):633-638.
  20. Roche N, Chapman KR, Vogelmeier CF et al ; Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Am J RespirCrit Care Med. 2017 Mar 9
  21. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J RespirCrit Care Med. 2008;178:1139-1147.
  22. Sethi S, Jones PW, Theron MS, et al; PULSE study group. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10.
  23. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. Dec 2008;63(12):1046-1051.
  24. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. EurRespir J. 2003;21:74-81.
  25. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
  26. Watz H, Tetzlaff K, Wouters EF et al ; Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016 May;4(5):390-8.
  27. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. The Lancet. Respiratory medicine. May 2013;1(3):199-209.
  28. Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361-368.
  29. Vogelmeier C, Hederer B, Glaab T, et al; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093-1103.
  30. Wedzicha JA, Miravitlles M, Hurst JR, and al ; Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. EurRespir J. 2017 Mar 15;49(3).